Agenda Item | Lead | Minutes |
|---|
Updates | | Connect a Thon, 1-5 March Virtual session; IHE USA; IT arm of HIMSS Reminder of four components Ask: please push/like/etc via social media All to be offered as standing webinar going forward Major impacts of this CAC for Connect a Thon
Objectives for 2021 to address after March; direction of this group; make ourselves available and good value-partner; August….real! How to look towards, prep for August HIMSS Make ourselves available; CAC is behind you, lets bring the key discussions to this group to help amp up the outcomes
March Meeting Prep
|
Value Based Care, ACS Equation (Frank) | | Quality over cost, elevate quality to value of cost Care in a value based direction, with cost in mind Issue: fatigue around value based care concept…evolution in how it is perceived To deliver at Enterprise level, some hurdles to overcome Frank inputs: Thrive Program with Harvard, episodes of care Expressing through Value Expression How to define Value Based Care and its subcomponents? Viewing value as a judgement; we each apply different perception components; it is personnel; difficult then to express from a data perspective Quality/Price; Costs required for this episode of care How to represent patient’s judgement; experiences and sensitivities; are we meeting their expectations and goals? Through: patient reported outcomes…get rid of pain, treated respectfully…respected end of life wishes…etc; series of plots like a radar plot/chart Outcome: add all the pieces of and then map them out Sensitivities: race, gender, background, etc….and how they overlay each other; expectations of health care system are very different; not sure what to expect vs. just want a good outcome vs other Clinical success is not always equal to value PROs as elements of the formula; PRO to be tailored to population being worked with; some are in place by researchers
Lee notes Value based care equated to bundled payment Quality of patient care for entire episode for least amt of $ being spent Drives better patient outcomes and drive down cost for patient care; outcome is that more of these are being rolled out more broadly National standard for bundles (Frank) in process, key for scaling; care is episodic once you get past transactions; did the outcome achieve the results? Note on price: match to disease, not being done (for most part) today; must consider overall amortized price eg 1 yr of outcomes vs 10 yr of outcomes (cost in the end for bad care) Corporation bundle model - required to be pitched to ind insurance companies, drives lack of standard for payment Where bundles working well? Poorly? Danville - profitable and high quality of care, seen as the gold standard Simple, procedural bundles 600 and conditioned bundles 200; conditional level is really the opportunity for savings moving forward CHF bundle this year as well not necessarily same as “carve-outs”
Final thoughts Frank: care model for each episode, resource model, come together with data models, all to inform, payment model, compensation model, competition, (value based); roles to play for several different aspects for implementation to be successful (ACTION: more discussion) How CAC to help? focus on quantification…make it a reality
|
ONC | | Broad discussion, how transition occurs, policy related, how best to structure; Overview Clear message through advocacy papers etc to help drive the standardization Also relates to brief/coordinate w FDA related to beneficial patterns (safety concern) Frank leading the policy workgroup How are we able to take CAC efforts to support Policy Group? How to make sure we don’t complicate?
Policy points ONC, FDA, CDC, CMS Looking to conversation with each agency, they each have public comment that will each hit WGs in different ways; how do they promote what we are doing; engage, be active, public comment both ways New ONC leadership - may not be as BPM tuned; so how do we engage? Behind the scenes, policy papers, public comment;
|
FDA, CDC and CMS (both to add) | | John FDA thoughts Need to engage w FDA Some processes are low risk, operational, procedural outside of FDA domain (eg scheduling) FDA has clear rules re drug prescription, etc with high regulation; Digital medicine is the group to engage with Need to meet certain criteria; Challenge with FDA - each drug or device requires separate submission, each taking two years to go through; that is big challenge for process automation FDA will approve the company, but not necessarily each individually; narrow set of models will be approved, so many processes not being brought forward Other issue is liability; challenge if components not aligned, there could be legal blame for failure; Davide has significant knowledge in this space
Davide two ways to engage: consumer of regulations, software as medical device, and second is do we need to encourage FDA to relax the rules/approach; FDA looking for AI guidance; Mayo contributed on this After FDA sets rules, how do we as producers of models relate to those rules? Most CDS is human in the loop, never considered FDA medical device, so issue is when we have full automation for safety, liability, etc…many nuances there
Shane notes Automation bringing for external sources forward, recs for forward pathways for clinicians, supplying them with info and they make decision necessary Provides loose decoupling between the system and the human making the decision; is this defensible?
|
Paper Criteria | Davide | AMIA, Causeway, call out for help, the ask |
| | |